Court Opinion

ID: 4469741
Source: CourtListenerOpinion
Date Created: 2020-01-07 13:02:24.680963+00
Date Added: 2024-06-11T08:48:58.088328
License: Public Domain

In the United States Court of Federal Claims
                                    No. 17-1580V
                              Filed: December 9, 2019
                      Reissued for Publication: January 6, 20201
    * * * * * * * * * * * * * * * * * **
                                                 *
    JESSICA HARDING,                             *
                      Petitioner,                *
                                                 *
    v.                                           * Vaccine Act; Motion for Review;
                                                 * Attorney’s  Fees   and   Costs;
    SECRETARY OF THE DEPARTMENT                  * Reasonable Basis.
    OF HEATH AND HUMAN SERVICES,                 *
                      Respondent.                *
                                                 *
                                                 *
    * * * * * * * * * * * * * * * * * **

         Mark T. Sadaka, Sadaka Associates LLC, Englewood, NJ, for petitioner.

        Voris E. Johnson, Senior Trial Attorney, Torts Branch, Civil Division, United
States Department of Justice, Washington, D.C., for respondent. With him were
Catharine E. Reeves, Deputy Director, Torts Branch, C. Salvatore D’Alessio, Acting
Director, Torts Branch, Civil Division, and Joseph H. Hunt, Assistant Attorney General,
Civil Division.
                                       OPINION

HORN, J.

       On October 20, 2017, petitioner, Jessica Harding, filed a request for vaccine
compensation under the National Vaccine Injury Compensation Program, 42 U.S.C.
§ 300aa-10 (2012) (Vaccine Program), in the United States Court of Federal Claims Office
of Special Masters. On August 20, 2018, petitioner filed an unopposed motion with
Special Master Thomas L. Gowen to dismiss her petition. On August 21, 2018, the Special
Master issued a “Decision on Entitlement,” dismissing petitioner’s claim for insufficient
proof. On February 28, 2019, petitioner filed an “Application for Attorney Fees and Costs,”
requesting $17,366.96 in attorney’s fees and costs.2 On June 18, 2019, the Special

1This Opinion was issued under seal on December 9, 2019. The parties did not propose
any redactions to the December 9, 2019 Opinion, and the court, therefore, issues the
Opinion without redactions for public distribution.
2The application itself states that petitioner requests “$27,366.96 for attorney’s fees and
costs,” but the record of time submitted with the application shows that the attorney’s fees
and costs totaled $17,366.96. In his decision on attorney’s fees and costs, Special Master
Gowen noted the discrepancy between the application and the underlying document
Master issued his “Decision on Attorneys’ Fees and Costs,” granting in full the petitioner’s
motion and awarding $17,366.96 in attorney’s fees and costs.3 See generally Harding v.
Sec’y of Health & Human Servs., No. 17-1580V, 2019 WL 3215974 (Fed. Cl. Spec. Mstr.
June 18, 2019). Respondent timely filed a motion for review of the Special Master’s
decision on the limited issue of attorney’s fees and costs in the United States Court of
Federal Claims.
                                   FINDINGS OF FACT
       According to the records before this court, petitioner Jessica Harding was born on
August 2, 1993 and resided in Albany, Oregon at the time she timely filed her petition for
compensation. Petitioner claimed that she suffered “vaccine induced aggravation of
Wegener’s granulomatosis, also known as granulomatosis polyangiitis [sic]” or GPA4 after
she received a second series of the three-shot human papillomavirus (HPV) vaccination
(brand name Gardasil). Twice petitioner received the series of the three-shot HPV
vaccination. Petitioner received the first series of three shots on April 2, 2009, January
28, 2010, and July 26, 2010. On August 30, 2010, petitioner saw Dr. Andrew Zeft at the
University of Utah’s Pediatric Rheumatology Clinic and described “having joint pain
everywhere” which petitioner reported as having begun in “early July 2010” and having
“persisted for approximately two months.” Petitioner also reported to Dr. Zeft that she had
been experiencing “bloody noses for the last three or four months.” On September 13,

submitted and stated that the “digit ‘2’ was most likely an inadvertent error.” Petitioner did
not dispute the Special Master’s assumption that the amount of the attorney’s fees and
costs claimed in her submissions totaled $17,366.96.
3 Special Master Gowen awarded attorney’s fees in the amount of $15,838.84, and costs
in the amount of $1,528.12. See Harding v. Sec’y of Health & Human Servs., 2019 WL
3215974, at *9.
4 In his decision on attorney’s fees and costs, Special Master Gowen cited the Mayo Clinic
definition of granulomatosis with polyangiitis or GPA, stating that “GPA specifically
‘causes inflammation of the blood vessels in your nose, sinuses, throat, lungs, and
kidneys,’” with signs and symptoms that “‘can develop suddenly or over several months,’”
and includes symptoms such as:

       “pus-like drainage with crusts from your nose, stuffiness, sinus infections
       and nosebleeds; coughing, sometimes with bloody phlegm, shortness of
       breath or wheezing; fever; fatigue; joint pain; numbness in your limbs,
       fingers, or toes; weight loss; blood in your urine; skin sores, bruising, or
       rashes; eye redness, burning or pain, and vision problems; [and] ear
       inflammation and hearing problems.”

Harding v. Sec’y of Health & Human Servs., 2019 WL 3215974, at *1, *3 (quoting Mayo
Clinic, Granulomatosis with Polyangiitis, https://www.mayoclinic.org/diseases-
conditions/granulomatosis-with-polyangiitis/symptoms-causes/syc-20351088 (last visited
Dec. 9, 2019)) (alteration in original).
                                              2
2010, Dr. Zeft diagnosed the petitioner with GPA. Petitioner was treated with
methotrexate and prednisone. Dr. Zeft made no notation in the records provided to the
court about petitioner having received the HPV vaccination.
        As indicated in petitioner’s exhibits submitted to Special Master Gowen, in 2012,
petitioner saw Dr. Stephen Parsons at PEAK ENT Associates with “severe rhinitis in the
LEFT nasal cavity, as well as sinusitis over the past couple of months,” and for a “RIGHT
middle ear effusion with some decreased hearing in the right ear.” (capitalization in
original). On May 1, 2012, petitioner underwent surgery for bilateral ear tube placement
to treat her hearing problems. The medical records submitted to the Special Master
indicate that petitioner’s symptoms began to worsen in late 2012. In October 2012,
petitioner saw Dr. Malgorzata Hanczyc at Central Utah Clinic in Provo, Utah with a sinus
infection and saw Dr. Parsons at PEAK ENT Associates complaining of significant pain
in her ear. Dr. Stephens noted, at that time, that petitioner’s GPA “seems to be under
good control.” In late February 2013, petitioner tested positive for C-ANCA. In May 2013,
petitioner saw Dr. Justin Jones at Central Utah Clinic with severe headache, nasal
pressure, and pain in her neck. In early October 2013, petitioner saw Dr. Jones
complaining of a chronic dry cough, and was diagnosed with asthma. In December 2013,
petitioner saw Dr. Yong Zhu, a rheumatologist with the Corvallis Clinic complaining of
“shortness of breath, intermittent nasal bleeding, and fatigue.” Dr. Zhu summarized
petitioner’s history of GPA, noting that “[s]he has been treated with prednisone therapy
for one year in combined [sic] with methotrexate. She has 3 years therapy of
methotrexate,” and “[d]uring the last a [sic] couple years, she gradually developed saddle
nose.”5 Petitioner also saw a pulmonologist, Dr. Vincent Gimino, in December 2013, who
noted that petitioner had developed “upper airway obstruction, most likely subglottic
stenosis related to underlying Wegener’s granulomatosis.”
        In January 2014, Dr. Nick Benton evaluated petitioner and noted “[t]he patient was
not well managed for a number of months and subsequently has had worsening
symptoms.” Dr. Benton noticed “issues with nasal Wegener’s with some nose bleeding
and nasal discharge,” but “did not see other evidence of tracheal involvement with
Wegener’s” other than “a thin subglottic stenosis,” which he believed would be “amenable
to dilation.” Dr. Zhu referred petitioner to rheumatologist Dr. Steven Call in Utah, who saw
petitioner on January 10, 2014 and noted that petitioner’s “airway is about 50% of what it
should be at this point.” Dr. Call placed petitioner on the drug Rituximab. On January 16,
2014, petitioner underwent surgical dilation for her subglottic stenosis. On February 11,
2014, petitioner saw Dr. Call for a follow-up appointment, and Dr. Call noted that petitioner
was moving back to Albany, Oregon to have the support of her family while she received
treatment for GPA. Dr. Call noted that petitioner had tapered her prednisone to 20 mg,
but experienced shortness of breath and he, therefore, increased her dose of prednisone
to 30 mg.

5“A ‘saddle nose deformity’ is defined as a ‘concavity of the contour of the bridge of the
nose due to collapse of cartilaginous or bony support, or both,’ which is associated with
GPA.” Harding v. Sec’y of Health & Human Servs., 2019 WL 3215974, at *4 n.8 (quoting
Dorland’s Illustrated Med. Dictionary 1291 (32nd ed. 2012)).
                                             3
       On April 26, 2014, petitioner saw Dr. Joshua Schindler, an otolaryngologist and
head and neck surgeon at the University of Oregon Health and Science University
(OHSU) – Northwest Clinic for Voice and Swallowing, for difficulty with her breathing. Dr.
Schindler’s assessment was that petitioner “appears to have dyspnea, hearing loss and
nasal collapse associated with granulomatosis with polyangiitis (GPA) that looks active
today on exam.” In July 2014, Dr. Schindler noted that petitioner’s airway was narrowed
after she saw him complaining of worsened breathing. Dr. Schindler then performed
another surgical dilation of her airway. By September 28, 2014, when petitioner returned
to Dr. Schindler for her first post-operative visit, petitioner told Dr. Schindler that she felt
better and was taking 40 mg of prednisone per day. In his assessment at that first post-
operative visit, Dr. Schindler noted that petitioner “looks better to me today than she did
in the operating room and has no signs of active nasal or subglottic granulomatosis with
polyangiitis (GPA).” Dr. Schindler also suggested that petitioner could wean her oral
steroid dose “as the Cytoxan becomes active.”
        Between 2014 and 2015, petitioner received the second series of the three shots
of the HPV vaccination. Petitioner received the first shot in the second series of the HPV
vaccination on October 28, 2014 from Dr. Kristin Berry, a gynecologist with Samaritan
Health Services. Dr. Berry had previously noted in petitioner’s records that petitioner was
starting on Cytoxan for treatment of her GPA and that petitioner’s physician
“recommended that the patient be on Lupon to suppress her ovaries during the time that
she is on Cytoxan as the medication can cause damage to her ovaries of [sic] not
protected.” Special Master Gowen noted that Dr. Berry’s physical assessment of
petitioner on October 28, 2014 “did not show signs of respiratory abnormalities or
distress.” Harding v. Sec’y of Health & Human Servs., 2019 WL 3215974, at *5. In his
decision, Special Master Gowen offered the following discussion of why Dr. Berry may
have started petitioner on another series of the HPV vaccination:
       The medical records from this visit do not reflect the petitioner previously
       completed a three-dose HPV vaccine series back in 2011. It is possible that
       petitioner needed a repeat course of HPV vaccine because her treatment
       for GPA, including chemotherapy drugs, wiped out her immune system. An
       alternative explanation could be that the medical provider giving the HPV
       vaccines in 2014 may not have been aware of the previous HPV vaccines
       administered at a different medical practice back in 2011. At any rate, it
       appears that in 2014, the gynecologist was aware of petitioner’s history of
       GPA but did not see any contraindication for administering the HPV vaccine.
Id.
       Two days later petitioner saw Dr. Schindler for a follow-up visit and he noted in his
assessment that she was taking 17.5 mg of prednisone and methotrexate. He indicated
that petitioner “continues to look good,” and that her GPA “does not appear active at this
time.” At this visit, petitioner informed Dr. Schindler that she had scheduled a rhinoplasty
for December 2014 with Dr. Wang. Dr. Schindler addressed his concerns about petitioner
undergoing surgery at length in his assessment, stating:
       I have grave concerns about her undergoing rhinoplasty in the next couple
       of months, however. She has not demonstrated adequacy of her
                                               4
       immunosuppression off prednisone yet and I fear that surgery to correct her
       saddle nose deformity and septal perforation could “reawaken” her disease.
       I would like to see her stably managed on methotrexate and quiescent for
       several months before surgery on a known site of activity for her. I fear that
       withdrawal of her immunosuppression around surgery for more than a brief
       period could result in reactivation of the GPA and loss of the reconstruction.
       We talked about this for a while and I promised that I would review my
       thoughts with Drs. Wang and Garg. My thoughts for her nasal surgery would
       be more like 6 months from now with demonstrated quiescence on
       methotrexate and off oral steroids.
Dr. Schindler increased petitioner’s prednisone dose to 27.5 mg per day for two weeks,
and then 25 mg per day for two weeks. The records submitted by petitioner suggest that
she did not undergo rhinoplasty until September 1, 2015.
        The second shot in the second HPV vaccination series was administered to
petitioner on November 25, 2014. On November 26, 2014, the next day, petitioner went
to her primary care practice complaining of stomach discomfort and urine smelling of
ammonia for two weeks. Petitioner’s records from the visit noted that petitioner was
tapering prednisone at 2.5 mg decrease every two weeks and was taking 10 mg of
prednisone per day at the time of her visit. Petitioner was diagnosed with abdominal pain
and fatigue and recommended for a follow-up visit with her primary care physician if her
symptoms did not improve. On December 2, 2014, petitioner returned to her primary care
practice complaining of “low energy, tapering off long term use of prednisone, increased
depression, headaches, some anxieties.” Petitioner’s medical records from this visit note
that she was taking 10 mg of prednisone per day as well as methotrexate. Petitioner’s
primary care physician, Dr. Rampton, assessed petitioner as having “Wegener’s
granulomatosis” with a note about tapering steroids, as well as headache, depression,
and anxiety, all of which he attributed to “[s]teroid withdrawal.”
       Almost two weeks later, on December 15, 2014, petitioner saw Dr. Schindler for a
follow-up visit and she said she was feeling “worse.” Petitioner underwent a pulmonary
function test and the results were “substantially worse than her prior study of 7/11/14.”
Dr. Schindler’s assessment was that petitioner “looks like her granulomatosis with
polyangiitis (GPA) is inadequately controlled with evidence of nasal, tracheobronchial and
advancing subglottic disease right now.” Dr. Schindler increased prednisone to 15 mg per
day for two weeks with instructions to taper by 2.5 mg every two weeks thereafter. Dr.
Schindler suggested making “adjustments to her immunosuppression to get better control
of the disease off prednisone.” Dr. Garg examined petitioner three days later, on
December 18, 2014, and assessed petitioner as having “active disease despite 6 cycles
of cytoxan.” Dr. Garg increased petitioner’s prednisone dose to 60 mg per day for two
weeks and then down to 40 mg per day while tapering down to 10 mg per day over three
months. On January 8, 2015, petitioner once again underwent surgical dilation of her
airway. On February 24, 2015, petitioner received her third and final shot for the second
series of the HPV vaccination. In the months following petitioner’s final shot for the second
series of the HPV vaccination, she continued to taper prednisone, but it was noted that in
March 2015 that “her disease appears to be quiescent.” Dr. Sibley, a rheumatologist in
Portland, Oregon, stated in progress notes forwarded to Dr. Rampton in August 2015 that

                                             5
petitioner “eventually achieved remission and has been treated with rituximab 375mg/kg
iv x 4 weekly doses starting 4/2015.”
        As indicated above, on October 20, 2017,6 petitioner filed her petition pursuant to
the Vaccine Program, and the case was assigned to Special Master Gowen. On October
26, 2017, petitioner filed exhibits of medical records, totaling more than 2,000 pages, to
try to support her claim. On November 6, 2017, Special Master Gowen ordered petitioner
to file any remaining medical records and a Statement of Completion by December 1,
2017. On December 1, 2017, petitioner filed an unopposed motion for extension of time
until January 30, 2018 because she had “ordered, but has not yet received, medical
records from all of her treating physicians.” Special Master Gowen granted petitioner’s
motion and ordered petitioner to file her outstanding medical records and a Statement of
Completion by January 30, 2018. On January 30, 2018, petitioner filed a second
unopposed motion for extension of time until March 30, 2018 to file medical records which
she indicated she had ordered but not yet received from “approximately five providers”
who petitioner had identified as potentially having medical records pertaining to her
injuries. The Special Master issued an order granting petitioner’s motion until March 30,
2018. The Special Master indicated that he would not view the petition as complete until
petitioner had filed a Statement of Completion, and that respondent’s status report was
to be filed within 60 days of the filing of petitioner’s Statement of Completion as opposed
to within 60 days of the initial filing of the petition pursuant to Vaccine Rule 4(a).
         On February 2, 2018, petitioner submitted an exhibit of medical records from her
gynecologist at Samaritan Health Services. On February 23, 2018, petitioner filed two
additional exhibits of medical records, the first from petitioner’s ophthalmologist at OHSU
and the second from petitioner’s gynecologist at OHSU. On March 29, 2018, petitioner
filed a third unopposed motion for extension of time until May 29, 2018, stating that
“[p]etitioner has one final medical record to submit which has been ordered and is in the
process of being obtained.” The Special Master granted in part, and, denied in part,
petitioner’s motion for extension of time, ordering that “Petitioner shall file the
outstanding medical records and a Statement of Completion within 45 days, by
Monday, May 14, 2018.” (emphasis in original). On May 14, 2018, petitioner filed a fourth
unopposed motion for extension of time until June 13, 2018, stating that the petitioner
had received “an invoice for the final medical record needed and is in the process of
obtaining.” On the following day, the Special Master granted petitioner’s motion.
       On June 13, 2018, petitioner filed a status report regarding how she planned to
proceed with her case. The status report stated: “Petitioner has indicated to her counsel
that she wishes to discontinue her case. Petitioner’s counsel respectfully requests thirty
(30) days or until July 13, 2018 to file a motion for a decision on this case.” On June 14,
2018, the Special Master issued an order granting petitioner’s request. On June 20, 2018,
Special Master Gowen issued an order informing the parties that “[t]he statutory 240-day
period for the special master’s issuance of a decision in this case has expired.” Petitioner

6There does not appear to be further information in petitioner’s October 20, 2017 petition
or Special Master Gowen’s decisions and orders about any medical developments
between August 2015 and the filing of the petition with the United States Court of Federal
Claims Office of Special Masters on October 20, 2017.
                                             6
was ordered to submit a notice continuing or withdrawing the petition within 30 days, or
by July 20, 2018.

        On July 13, 2018, petitioner submitted a request for a status conference “to discuss
next steps.” Special Master Gowen held a status conference on July 19, 2018. In an
Order to Show Cause issued on the same day, July 19, 2018, the Special Master
indicated that during the status conference, Mr. Sadaka, petitioner’s counsel of record,
“stated that petitioner had verbally indicated that she wished to discontinue her claim in
the Vaccine Program. However, petitioner has been unwilling or unable to send Mr.
Sadaka her written authorization.” The Special Master “agreed that Mr. Sadaka needs
petitioner’s cooperation to either discontinue or continue with her claim.” Special Master
Gowen, therefore, ordered petitioner:
        [T]o either file all remaining medical records and a Statement of
       Completion or deliver to counsel her written authorization to
       discontinue her claim within 30 days, by Monday, August 20, 2018.
       Petitioner’s failure to comply with this Order will be interpreted as a
       failure to prosecute her claim, which will result in its involuntary
       dismissal.
(emphasis in original).
       On August 20, 2018, petitioner filed an unopposed “Motion for a Decision
Dismissing her Petition.” In her motion, petitioner stated that she “understands that a
decision by the Special Master dismissing her petition will result in a judgment against
her,” and that “[s]he has been advised that such a judgment will end all of her rights in
the Vaccine Program.” The motion stated further that:
       Petitioner understands that she may apply for costs once her case is
       dismissed and judgment is entered against her. Petitioner’s counsel has
       contacted respondent’s counsel regarding respondent’s position on this
       motion and understands that respondent expressly reserves the right,
       pursuant to 42 U.S.C. § 300aa-15(e), to question the good faith and
       reasonable basis of her claim and to oppose, if appropriate, her application
       for costs. Respondent otherwise does not oppose this motion [sic]
On August 21, 2018, the Special Master issued a “Decision on Entitlement,” dismissing
petitioner’s claim for insufficient proof. In his decision, Special Master Gowen stated:
       Under the Vaccine Act, the Program may not award compensation solely
       based on a petitioner’s own claims. Rather, a petitioner must support his
       [sic] claim with either medical records or the opinion of a competent
       physician. § 13(a)(1). The undersigned also notes that in his experience,
       significant aggravation claims can be particularly fact-intensive. Such a
       claim involves obtaining considerable medical records. It also involves
       comparing the petitioner’s condition before and after the vaccination(s) at
       issue, and considering the possible course of the condition “but for” those
       vaccination(s). This further illustrates the importance of obtaining medical

                                             7
       records as well as a supportive opinion from a competent physician.
       However, petitioner has not filed these materials.
Judgment was entered by the Clerk of Court of the United States Court of Federal Claims
on September 21, 2018, which stated: “Pursuant to the special master’s decision, filed
August 21, 2018, IT IS ORDERED AND ADJUDGED this date, pursuant to Vaccine Rule
11(a), that the case is dismissed for insufficient proof.” (capitalization in original). The
judgment also indicated that a motion for attorney’s fees and costs need to be filed by
represented petitioners within 180 days of judgment.
       On February 28, 2019, petitioner filed an “Application for Attorney Fees and Costs”
requesting $17,366.96. In her “Application for Attorney Fees and Costs,” petitioner
asserted that she had brought her claim in good faith because she “developed a relapse
of GPA within 30-days after receiving a fourth Gardasil vaccine in October of 2014.”
Petitioner further asserted that under the totality of the circumstances analysis enunciated
in Chuisano v. United States, 116 Fed. Cl. 276 (2014), the court should find that petitioner
had a reasonable basis to bring her claim. Petitioner explained that because “[h]er GPA
clearly started after the second Gardasil vaccine Petitioner received in 2010. At least one
medical provider stated that her GPA was in remission around the time Petitioner received
the fourth Gardasil vaccination. Finally, the record is clear that her health rapidly
decompensated within 30-days thereafter.” Based on the forgoing, petitioner argued that
there was a reasonable basis to bring the claim.

         On March 8, 2019, respondent filed a response opposing petitioner’s “Application
for Attorney Fees and Costs” on the grounds “that petitioner has failed to establish a
reasonable basis for her claim.” Respondent asserted that, under the United States Court
of Appeals for the Federal Circuit’s holding in Simmons v. Secretary of Health & Human
Services, “the reasonable basis analysis must focus on whether there is evidentiary
support for the claim set forth in the petition, not whether counsel acted reasonably in
filing the petition.” (citing Simmons v. Sec’y of Health & Human Servs., 875 F.3d 632, 636
(Fed. Cir. 2017)). Respondent stated that “[p]etitioner has not identified (nor has
respondent located) any notation in the medical records indicating that her treating
physicians believed the HPV vaccine played any role in causing or exacerbating her
condition, nor has petitioner provided an expert report in support of her claim.”
Respondent further stated that “absent any objective evidence that the HPV vaccine
caused or significantly aggravated petitioner’s alleged injury, the claim has no feasibility
of success,” and, therefore, no reasonable basis for the claim has been established.
        Special Master Gowen issued his “Decision on Attorneys’ Fees and Costs” on June
18, 2019, granting in full the petitioner’s motion and he awarded petitioner $17,366.96 in
attorney’s fees and costs. See Harding v. Sec’y of Health & Human Servs., 2019 WL
3215974, at *9. In his decision, the Special Master stated that petitioner was time-barred
from claiming that the first series of HPV vaccinations was the cause-in-fact of her GPA
because the vaccinations and the onset of her GPA symptoms “were well outside of the
statute of limitations set forth by the Vaccine Act. § 16(a)(2).” Harding v. Sec’y of Health
& Human Servs., 2019 WL 3215974, at *1. The Special Master further noted that the
petition did not demonstrate “a strong temporal association between HPV vaccines and
the original onset of petitioner’s GPA in 2010,” and further, at the time petitioner moved

                                             8
to dismiss the petitioner, petitioner had not “provided any treating physician or expert’s
opinion supporting vaccine causation for the original onset,” but that lack of support “does
not rule out reasonable basis for petitioner’s claim that the second round of HPV
vaccinations significantly aggravated that condition.” Id. at *4.
       In granting petitioner’s request, the Special Master discussed the factual findings
summarized above, with references to the filings submitted by both parties. See id. at *3-
6. The Special Master offered his analysis of the facts in the record, including:
       The medical records from late September and October 2014 do not
       expressly say that petitioner was in “remission” before receiving the HPV
       vaccines at issue in the significant aggravation claim. However, those
       records do suggest that her condition was improving and approaching
       quiescience [sic]. Additionally, the medical records reflect that within 30
       days after petitioner received the first HPV vaccine at issue, petitioner did
       experience of [sic] GPA. Indeed, within 45 days after the HPV vaccine, Dr.
       Schindler, the doctor managing her GPA, confirmed the flare and recorded
       that her condition was “inadequately controlled.”

Id. at *6. The Special Master also discussed a possible course of petitioner’s claim had
she not filed a motion for a decision dismissing the claim, stating:

       If petitioner had filed her remaining medical records and a statement of
       completion and the case proceeded on a litigation track, I likely would have
       authorized petitioner to seek a further statement or an expert opinion as to
       whether the vaccines, which are designed to cause an immune response,
       can cause or substantially contribute to a flare of GPA, an autoimmune
       condition during the vulnerable time period while prednisone (an
       immunosuppressant) is being tapered down. See, e.g., Shyface v. Sec'y of
       Health & Human Servs., 165 F.3d 1344 (Fed. Cir. 1999) (holding that a
       petitioner may prevail on entitlement by demonstrating that a vaccine was
       a “substantial factor” contributing to the injury). I would also question
       whether there is evidence that the HPV vaccines administered to petitioner
       in 2014 - 2015 did cause or contribute to a flare of her GPA, whether that
       flare constituted a significant aggravation of her GPA, and whether the
       timing was medically acceptable. See Althen v. Sec’y of Health & Human
       Servs., 17 F.3d 374 (Fed. Cir. 1994) [sic]; Loving v. Sec’y of Health &
       Human Servs., 86 Fed. Cl. 135, 144 (2009), see also W.C. v. Sec'y of Health
       & Human Servs., 704 F.3d 1352 (Fed. Cir. 2007). I would also ask whether
       petitioner's post-vaccination course was simply “consistent with the usual
       course of GPA and/or associated changes in her medications,” as
       respondent argues for the first time in his response contesting reasonable
       basis. This may be a valid argument, but in my view, it would be more
       appropriately addressed at a later stage in the claim with the input of
       qualified medical experts.

       However, before the case reached that stage, petitioner requested a
       dismissal decision. When she did, the claim had been pending for ten
                                             9
       months. It had taken petitioner and her counsel significant time to obtain
       thousands of pages of medical records from providers in at least two states.
       She was still working to obtain the remaining medical records and a
       statement of completion. I had not provided my preliminary view of the claim
       (except for noting that any alleged injuries from the 2009 – 2010 HPV
       vaccines were time-barred). Respondent had not filed a [Vaccine] Rule 4(c)
       report or even a status report providing his view of the claim. Therefore,
       petitioner and her counsel appear to have made an independent decision
       to dismiss the claim, not because of any issues that had been clearly
       identified for them. In my experience, a petitioner sometimes decides to
       dismiss a claim for personal reasons such as improvement of his or her
       medical status, wanting to move on with his or her life, and the delays
       currently present in the Vaccine Program. The decision may also be based
       on prudent advice from counsel with experience in the Program.

Harding v. Sec’y of Health & Human Servs., 2019 WL 3215974, at *7 (internal citation
omitted). The Special Master further noted that petitioner’s motion for a dismissal decision
“did not state that the evidence was insufficient to bring her claim.” Id. The Special Master
concluded: “In sum, I find that the medical records documenting a flare of an autoimmune
disease shortly after administration of a covered vaccine provided reasonable basis for
filing this petition and for pursuing it until the voluntary dismissal at an early stage.” Id.
(footnote omitted). The Special Master stated in a footnote that “[i]f the claim had
proceeded, it may have lost reasonable basis at some point. However, that did not occur
here. My determination is based on the limited filings and procedural history before me.”
Id. at *7 n.9.

       Respondent timely filed a motion for review of the Special Master’s decision on
attorney’s fees and costs on July 15, 2019 in the United States Court of Federal Claims.7
In the instant case, respondent argues that “[t]he special master violated Simmons [v.
Secretary of Health & Human Services, 875 F.3d 632 (Fed. Cir. 2017)] by improperly
considering the conduct of petitioner’s counsel in his reasonable basis analysis.”
Respondent further argues that “[e]ven if the special master had not improperly
considered counsel’s conduct in his reasonable basis analysis, the Decision still
constitutes legal error because the special master did not ground his analysis in an
evaluation of the objective record evidence,” claiming that the Special Master’s analysis
“rested almost entirely on his subjective interpretation of the medical records and his

7 This court notes the inconsistency in respondent’s posture in this case and in other
vaccine cases, such as McIntosh v. Secretary of Health & Human Services, 139 Fed. Cl.
238 (2018) and Dominguez v. Secretary of Health & Human Services, 136 Fed. Cl. 779
(2018), in which respondent declined to review petitioners’ submitted requests for
attorney’s fees and costs, indicating it was the role of the special master, not the
respondent. Both with respect to issues such as “reasonable basis” and the amount of
attorney’s fees and costs claimed by a petitioner, the Special Master is entitled to receive
the input of the respondent represented by the United States Department of Justice on
petitioner’s claims for attorney’s fees and costs, not just when the respondent chooses to
do so.
                                             10
speculation about what the evidence might have been if petitioner had decided to proceed
with the case.” The respondent has not challenged the amount of the fees and costs
awarded, only whether there was a “reasonable basis” for the claim.

        Petitioner filed a memorandum in opposition to respondent’s motion for review on
the issue of the Special Master’s award of attorney’s fees and costs and petitioner argues
that after a thorough evaluation of several objective factors, the Special Master concluded
that an award for attorney fees and costs “was appropriate in this case.”8 Petitioner states
that “[b]ecause respondent has not shown that the Special Master erred, or that his factual
findings and legal determinations were arbitrary, capricious, an abuse of discretion, or
otherwise not in accordance with law, his decision should be affirmed.”

                                     DISCUSSION

       When reviewing a special master’s decision, the assigned Judge of the United
States Court of Federal Claims may:

         (A) uphold the findings of fact and conclusions of law of the special master
         and sustain the special master’s decision,

         (B) set aside any findings of fact or conclusions of law of the special master
         found to be arbitrary, capricious, an abuse of discretion, or otherwise not in
         accordance with law and issue its own findings of fact and conclusions of
         law, or

         (C) remand the petition to the special master for further action in accordance
         with the court’s direction.

42 U.S.C. § 300aa-12(e)(2). The legislative history of the Vaccine Act states: “The
conferees have provided for a limited standard for appeal from the [special] master's
decision and do not intend that this procedure be used frequently, but rather in those
cases in which a truly arbitrary decision has been made." H.R. Rep. No. 101-386, at 517
(1989) (Conf. Rep.), reprinted in 1989 U.S.C.C.A.N. 3018, 3120.

        Regarding the standard of review, in Markovich v. Secretary of Health and Human
Services, the United States Court of Appeals for the Federal Circuit wrote, “[u]nder the
Vaccine Act, the Court of Federal Claims reviews the Chief Special Master's decision to
determine if it is ‘arbitrary, capricious, an abuse of discretion, or otherwise not in
accordance with the law.’ 42 U.S.C. § 300aa-12(e)(2)(B).” Markovich v. Sec’y of Health
& Human Servs., 477 F.3d 1353, 1355-56 (Fed. Cir.), cert. denied, 552 U.S. 816 (2007);
see also Deribeaux ex rel. Deribeaux v. Sec’y of Health & Human Servs., 717 F.3d at
1366 (The United States Court of Appeals for the Federal Circuit stated that “we ‘perform[
] the same task as the Court of Federal Claims and determine[ ] anew whether the special
master's findings were arbitrary or capricious.’” (quoting Lampe v. Sec’y of Health &
Human Servs., 219 F.3d 1357, 1360 (Fed. Cir. 2000))) (brackets in original); W.C. v. Sec’y

8   Neither party challenges Special Master Gowen’s “Decision on Entitlement.”
                                              11
of Health & Human Servs., 704 F.3d at 1355; Hibbard v. Sec’y of Health & Human Servs.,
698 F.3d 1355, 1363 (Fed. Cir. 2012); Avera v. Sec’y of Health & Human Servs., 515
F.3d 1343, 1347 (Fed. Cir.) (“Under the Vaccine Act, we review a decision of the special
master under the same standard as the Court of Federal Claims and determine if it is
‘arbitrary, capricious, an abuse of discretion, or otherwise not in accordance with law.’”
(quoting 42 U.S.C. § 300aa-12(e)(2)(B))), reh’g and reh’g en banc denied (Fed. Cir.
2008); de Bazan v. Sec’y of Health & Human Servs., 539 F.3d at 1350; Althen v. Sec’y of
Health & Human Servs., 418 F.3d 1274, 1277 (Fed. Cir. 2005); Dodd v. Sec’y of Health
& Human Servs., 114 Fed. Cl. 43, 47 (2013); Taylor v. Sec’y of Health & Human Servs.,
108 Fed. Cl. 807, 817 (2013). The arbitrary and capricious standard is “well understood
to be the most deferential possible.” Munn v. Sec’y of Health & Human Servs., 970 F.2d
863, 870 (Fed. Cir. 1992). “‘Not in accordance with the law’ refers to the application of the
wrong legal standard, and the application of the law is reviewed de novo.” Rodriguez v.
Sec’y of Health & Human Servs., 632 F.3d 1381, 1384 (Fed. Cir. 2011) (citing Markovich
v. Sec’y of Health & Human Servs., 477 F.3d 1353, 1356 (Fed. Cir. 2007)); see also
Dougherty v. Sec’y of Health & Human Servs., 141 Fed. Cl. 223, 229 (2018) (“With
respect to findings of fact, the special masters have broad discretion to weigh evidence
and make factual determinations. As to questions of law, the legal rulings made by a
special master in connection with a vaccine claim are reviewed de novo, under a ‘not in
accordance with the law’ standard.”).

       Regarding attorneys’ fees and costs, the Vaccine Act at 42 U.S.C. § 300aa-
15(e)(1), provides:
              (1) In awarding compensation on a petition filed under section 300aa-
              11 of this title the special master or court shall also award as part of
              such compensation an amount to cover--
              (A) reasonable attorneys’ fees, and
              (B) other costs, incurred in any proceeding on such petition. If the
              judgment of the United States Court of Federal Claims on such a
              petition does not award compensation, the special master or court
              may award an amount of compensation to cover petitioner’s
              reasonable attorneys’ fees and other costs incurred in any
              proceeding on such petition if the special master or court determines
              that the petition was brought in good faith and there was a
              reasonable basis for the claim for which the petition was brought.
42 U.S.C. § 300aa-15(e)(1); see also Shaw v. Sec’y of Health & Human Servs., 609 F.3d
1372, 1375 (Fed. Cir. 2010).

        “In Vaccine Act cases before this Court contesting a special master's determination
of reasonable attorney’s fees, the applicable standard of review is abuse of discretion.”
Scharfenberger v. Sec’y of Health & Human Servs., 124 Fed. Cl. 225, 231 (2015) (citing
Hall v. Sec'y of Health & Human Servs., 640 F.3d 1351, 1356 (Fed. Cir. 2011) ), appeal
dismissed (Fed. Cir. 2016); see also Dominguez v. Sec’y of Health & Human Servs., 136
Fed. Cl. at 782. As indicated by the Federal Circuit in Hall, “Section 300aa–15(e) states

                                             12
that ‘the special master or court shall also award as part of such compensation an amount
to cover . . . reasonable attorneys’ fees.’ Thus, the statute leaves it to the special master's
discretion to find what constitutes reasonable fees.” Hall v. Sec’y of Health & Human
Servs., 640 F.3d at 1356. As explained in Carter v. Secretary of Health & Human
Services: “As an initial matter, the record before the Court shows that the special master
correctly defined the reasonable basis standard under Section 15(e) of the Vaccine Act.
The Court reviews the special master's legal determination regarding the meaning of the
Vaccine Act's reasonable basis standard de novo.” Carter v. Sec’y of Health & Human
Servs., 132 Fed. Cl. 372, 379 (2017) “If the petition for compensation is denied, the
special master ‘may’ award reasonable fees and costs if the petition was brought in good
faith and upon a reasonable basis; the statute clearly gives him discretion over whether
to make such an award.” Saxton By & Through Saxton v. Sec’y of Health & Human Servs.,
3 F.3d 1517, 1520 (Fed. Cir. 1993) (citing Perreira v. Sec’y of Health & Human Servs., 27
Fed. Cl. 29, 31 (1992)).

       In the above captioned case, the respondent does not allege that the petition was
not brought in good faith, only whether there was a reasonable basis for bringing the
claim. Because respondent argues that “[t]he primary issue in this appeal is whether the
special master correctly applied the law as stated in Simmons,” this court reviews the
issue de novo. See Rodriguez v. Sec’y of Health and Human Servs., 632 F.3d at 1384.

        The Vaccine Act, pursuant to which attorney’s fees and costs can be awarded, is
silent as to the definition of “reasonable basis.” See 42 U.S.C. § 300aa-15(e)(1) (2012).
The Court of Appeals for the Federal Circuit however, has explained, “good faith” and
“reasonable basis” determinations are distinct, and that “only ‘good faith’ is subjective,”
while “‘reasonable basis is objective.’” Simmons v. Sec’y of Health & Human Servs., 875
F.3d 632, 635 (Fed. Cir. 2017) (citing Chuisano v. United States, 116 Fed. Cl. at 289);
see also Simmons v. Sec’y of Health & Human Servs., 128 Fed. Cl. 579, 582 (2016)
(citing Chuisano v. United States, 116 Fed. Cl. at 289) (“Good faith and reasonable basis
are ‘two distinct facets’ that must be judged separately.”), aff’d, 875 F.3d 632 (Fed. Cir.
2017).

       One special master described the review of whether there was a reasonable basis
in order to award attorney’s fees and costs as follows:

       A special master must award reasonable fees and costs to a petitioner who
       receives compensation under the Vaccine Act. 42 U.S.C. § 300aa-15(e)(1)
       (2012). Although not required to do so, the special master may also award
       reasonable fees and costs to an unsuccessful petitioner, so long as the
       petitioner (1) filed the petition in good faith and (2) had a reasonable basis
       for the claim. Id.

       Of note, the Vaccine Act does not compel the special master to make an
       award to every petitioner who meet these requirements; rather, Congress
       vested the special master with discretion and “plainly contemplat[ed] that
       not all petitioners would recover fees and costs.” Chuisano v. United States,
       116 Fed. Cl. 276, 286 (2014). To be sure, the special master's discretion is

                                              13
      tempered by the remedial nature of the Vaccine Act, which necessitates
      liberally construing its provisions to effectuate its ultimate goal: “to award
      compensation to vaccine-injured persons quickly, easily, and with certainty
      and generosity.” Cloer v. Sec’y of HHS, 675 F.3d 1358, 1362 (Fed. Cir.
      2012) (internal quotation marks omitted).

      With regard to the good faith requirement, the Court of Federal Claims has
      observed that petitioners “are entitled to a presumption of good faith.” Grice
      v. Sec’y of HHS, 36 Fed. Cl. 114, 121 (1996). In other words, when there is
      no “direct evidence of bad faith,” the special master is justified in finding that
      Petitioner has met the good faith requirement. Id.

      As to the existence of a reasonable basis for filing the claim, the Vaccine
      Act “grants to the special master maximum discretion in applying the
      standard.” Silva v. Sec’y of HHS, 108 Fed. Cl. 401, 402 (2012). Functionally,
      “reasonable basis is an objective standard determined by the totality of the
      circumstances.” Chuisano, 116 Fed. Cl. at 286. Although insusceptible to
      precise definition, a petitioner attempting to meet this standard faces a
      burden that “is something less than the preponderant evidence ultimately
      required to prevail on one's vaccine-injury claim.” Id. at 287.

Mounts v. Sec’y of Health and Human Servs., No. 14-1219V, 2016 WL 4540344, at *5-6
(Fed. Cl. Spec. Mstr. July 27, 2016) (footnote omitted) (emphasis and alteration in
original).

       Reasonable basis may exist at the initial filing of a petition for compensation, but
can dissipate as further evidence is introduced that undermines that basis. See Perreira
v. Sec’y of Health & Human Servs., 33 F.3d at 1377.9 For example, as indicated in
Perreira v. Secretary of Health & Human Services, “once petitioners-appellants reviewed
the expert opinion upon which their case depended, they no longer had a reasonable
basis for claiming causation in-fact because the expert opinion was grounded in neither
medical literature nor studies.” Id. In Cottingham v. Secretary of Health & Human
Services, a Judge of the United States Court of Federal Claims vacated a special master's
decision denying attorney’s fees and costs and remanded to the special master to “apply

9 In Bilodeau v. Secretary of Health & Human Services, after filing a petition, the
petitioners moved for a decision dismissing their petition, which the special master
granted. See Bilodeau v. Sec’y of Health & Human Servs., No. 14-72V, 2017 WL
2417926, at *1 (Fed. Cl. Spec. Mstr. May 9, 2017). Subsequently, the petitioners moved
for attorney’s fees and costs. In response, the respondent argued that attorney’s fees and
costs were inappropriate “stating that ‘[t]he case lacked a reasonable basis at the time
the petition was filed, and petitioners failed to obtain evidence to satisfy the reasonable
basis requirement during the pendency of the case,’ arguing that all attorneys’ fees and
costs should be denied.” Id. The special master disagreed with respondent’s
characterization and awarded petitioners the full amount of attorney’s fees and costs
sought. See id. at *10-11.

                                             14
a totality of the circumstances standard and reassess whether Petitioner's claim had a
reasonable basis at the time the petition was filed and at intervals when additional
evidence became available to Petitioner’s counsel thereafter.” Cottingham v. Sec'y of
Health & Human Servs., 134 Fed. Cl. 567, 578 (2017).10 It is appropriate for a special
master to consider whether if a reasonable basis existed at the time the case was
resolved when making a determination on the appropriateness of attorney’s fees and
costs. In the above captioned case, Ms. Harding had provided some, but perhaps not all,
of the relevant medical records when the case was dismissed, and according to petitioner,
she was still trying to obtain additional records. Special Master Gowen, therefore, had to
determine if petitioner had a reasonable basis to bring her claims, although the record
was as yet incomplete. The Special Master was obligated to rely on the medical records
in the case, but his speculations about the future if the case had continued are not relevant
to his decision on attorney’s fees and costs and should not be given deference. Despite
his musings and occasional speculation on what would have happened in the future,
based on the medical records before him, it appears Special Master Gowen had a basis
to conclude that the petition was filed in good faith and that there was a “reasonable basis”
for petitioner to file the petition and to peruse her claims.

        The respondent relies on Simmons, a decision issued by the United States Court
of Appeals for the Federal Circuit in 2017, which considered whether there was
reasonable basis for a petitioner’s claim when petitioner’s counsel filed a petition for
compensation based on an occurrence of Guillain-Barré syndrome shortly before the
statute of limitations in the case would have expired. See Simmons v. Sec’y of Health &
Human Servs., 875 F.3d at 634. The petition in Simmons ultimately was dismissed for
failure to prosecute by the special master, but the special master nevertheless awarded
attorney’s fees, finding as a reasonable basis that because the statute of limitation was
set to expire, “‘[t]o not file a petition . . . would be tantamount to an ethical violation.’” Id.
(quoting Simmons v. Sec’y of Health & Human Servs., 2016 WL 2621070, at *3 (Fed. Cl.
Spec. Mstr. Apr. 14, 2016), rev’d, 128 Fed. Cl. 579 (2016), aff’d, 875 F.3d 632 (Fed. Cir.
2017)) (alteration in original). The special master in Simmons noted that “Petitioner
provided only the receipt of his vaccination, which occurred on October 26, 2010,” and
the special master focused on the fact that after an initial meeting, “[d]uring the next year
and a half, Counsel attempted to contact Petitioner on at least 20 separate occasions via

10 The court notes that this Cottingham decision, Cottingham v. Secretary of Health &
Human Services, 134 Fed. Cl. 567, is one of three, distinct opinions issued by the United
States Court of Federal Claims named Cottingham referenced in this Opinion. All three
opinions relate to the same petitioner. The first two Cottingham decisions, Cottingham v.
Secretary of Health & Human Services, 134 Fed. Cl. 567 and Cottingham v. Secretary of
Health & Human Services, 139 Fed. Cl. 88 (2018) remanded the case back to the special
master. The third and final Cottingham decision, Cottingham v. Secretary of Health &
Human Services, 141 Fed. Cl. 85 (2018) denied the petitioner’s motion for review.
Cottingham v. Secretary of Health & Human Services, 141 Fed. Cl. 85, is currently on
appeal to the United States Court of Appeals for the Federal Circuit. The court notes that
the first Cottingham decision, Cottingham v. Secretary of Health & Human Services, 134
Fed. Cl. 567 was decided prior to the Federal Circuit’s decision in Simmons.
                                               15
email, telephone, and written letter, in order to follow up on their initial meeting and obtain
Petitioner’s medical records,” but was only able to reach the Simmons petitioner on two
occasions. See id. at *1. The special master in Simmons emphasized that “nine days
before the statute of limitations deadline was due to expire, Petitioner called Counsel,
asking ‘to move forward’ with his claim,” but “[o]ver the next seven months, Counsel
sought out Petitioner in myriad ways but was unable to contact him.” Id. at *2.

       The United States Court of Federal Claims in Simmons reversed the special
master’s decision, finding that the special master had erred in her reasonable basis
analysis because “‘[t]he fact that the statute of limitations was about to expire did not
excuse counsel’s obligation to show he had some basis for the claim beyond his
conversation with the petitioner.’” Simmons v. Sec’y of Health & Human Servs., 875 F.3d
at 634 (quoting Simmons v. Sec’y of Health & Human Servs., 128 Fed. Cl. 579, 584
(2016)). The United States Court of Appeals for the Federal Circuit upheld the decision
of the United States Court of Federal Claims, stating:

       The Vaccine Act provides that there must be a “reasonable basis for the
       claim for which the petition was brought” before the special master may
       exercise her discretion in awarding attorneys’ fees. 42 U.S.C. § 300aa–
       15(e)(1) (emphasis added). Whether there is a looming statute of limitations
       deadline, however, has no bearing on whether there is a reasonable factual
       basis “for the claim” raised in the petition. That is an objective inquiry
       unrelated to counsel’s conduct. Although an impending statute of limitations
       deadline may relate to whether “the petition was brought in good faith” by
       counsel, the deadline does not provide a reasonable basis for the merits of
       the petitioner’s claim. Id.

Simmons v. Sec’y of Health & Human Servs., 875 F.3d at 636 (emphasis in original). The
Federal Circuit concluded:

       [C]ounsel may not use this impending statute of limitations deadline to
       establish a reasonable basis for Mr. Simmons’s claim. Because the special
       master only found that there was a reasonable basis for Mr. Simmons’s
       claim because of the impending statute of limitations deadline, we conclude
       that she abused her discretion by misapplying the law. Accordingly, we
       affirm the Claims Court’s decision.

Id. (emphasis added). A difference between the current case and Simmons appears in
the records before the two courts, as the Simmons case had virtually no documentation
before the special master with only the receipt of his vaccination and nothing else having
been submitted after the petition was filed. The record in the case currently before this
court, in addition to the petition, includes over 2,000 pages of medical records submitted
by petitioner, some of which appear to raise sufficient issues for Ms. Harding to have had
a reasonable basis to file a vaccine petition with the United States Court of Federal Claims
Office of Special Masters.

                                              16
        As indicated by a Judge of the United States Court of Federal Claims in Cottingham
v. Secretary of Health & Human Services, 141 Fed. Cl. 85, “[t]he Court in Simmons was
presented with a narrow issue -- whether an imminent statute of limitations deadline could
be considered in assessing whether the petitioner's claim had a reasonable basis” to file
the petition. See id. at 88. Moreover, the Cottingham court explained, “[t]hus, under
Simmons, a special master may consider the evidence a petitioner provided, such as
medical records and affidavits, in determining whether a reasonable basis for the claim
exists.” Id. As noted above, in the Simmons case, the Simmons petitioner only filed one
document, proof of his vaccination and nothing else. Moreover, Mr. Simmons’ attorney
repeatedly tried to contact his client, on at least twenty occasions over a period of a year
and a half, by email, telephone, and by letter. After counsel’s initial contact with his client,
petitioner’s counsel could generally not reach his client after the petition was filed.
Notably, unlike in Ms. Harding’s case in which her petition was dismissed following her
motion for a decision to dismiss her petition, the special master in Simmons dismissed
the case for failure to prosecute. Finally, nowhere in Special Master Gowen’s decision did
he address the statute of limitations, which was the focus of the special master’s decision
in Simmons, except to note that the statute of limitations barred petitioner’s earlier HPV
vaccination was a cause in fact of her GPA. See Harding v. Sec’y of Health & Human
Servs., 2019 WL 3215974, at *1.
       More recently, a Judge of the United States Court of Federal Claims addressed
the impact of the Federal Circuit’s holding in Simmons regarding the reasonable basis
analysis in Amankwaa v. Secretary of Health & Human Services, 138 Fed. Cl. 282 (2018).
In Amankwaa, the court stated that prior to Simmons:

       [T]he Court of Federal Claims generally endorsed the use of a totality-of-
       the-circumstances analysis to determine whether there was a reasonable
       basis for a claim. See Cottingham v. Sec’y of HHS, 134 Fed. Cl. 567, 574
       (2017). Specifically, special masters were expected to “consider the
       circumstances under which the petition is filed, any jurisdictional questions,
       the factual basis and medical support for the petition, and any other legal
       issues that may arise.” Id. at 574–75; see also id. at 574 (observing that
       special masters have the “discretion to consider multiple potentially relevant
       circumstances—such as the novelty of the vaccine, scientific understanding
       of the vaccine and its potential consequences, the availability of experts and
       medical literature, and the time frame counsel has to investigate and
       prepare the claim—in assessing whether a Vaccine Act claim has a
       reasonable basis”). Further, “[t]his totality of the circumstances assessment
       [was to] take into account evidence available at the time a claim is filed and
       evidence that becomes available as the case progresses.” Id. at 575.

Amankwaa v. Sec’y of Health & Human Servs., 138 Fed. Cl. at 287 (alteration in original).
According to the Amankwaa court’s reading of Simmons, “the Federal Circuit forbade,
altogether, the consideration of statutory limitations deadlines-and all conduct of counsel-
in determining whether there was a reasonable basis for a claim.” Amankwaa v. Sec’y of
Health & Human Servs., 138 Fed. Cl. at 289. The Amankwaa court further concluded that
Simmons prohibited special masters from considering any subjective factors in

                                              17
determining whether a claim had reasonable basis, but rather they must focus their
analyses on objective factors, “such as the factual basis of the claim, the medical and
scientific support for the claim, the novelty of the vaccine, and the novelty of the theory of
causation.” Id. (citing Cottingham v. Sec’y of Health & Human Servs, 134 Fed. Cl. at 574)
(footnote omitted).

        The United States Court of Federal Claims also addressed the impact of Simmons
on a special master’s reasonable basis analysis in Cottingham v. Secretary of Health &
Human Services, 139 Fed. Cl. 88. The court in Cottingham v. Secretary of Health &
Human Services, 139 Fed. Cl. 88, held that, in light of the issuance of Simmons while a
petitioner’s case was pending before the special master on remand, the special master
“shall, consistent with Simmons, analyze whether the evidence alone was sufficient for
finding a reasonable basis for Petitioner’s claim, without considering the conduct of
counsel or the impending statute of limitations.” Cottingham v. Sec’y of Health & Human
Servs, 139 Fed. Cl. at 94.

      In his decision on attorney’s fees and costs in the case currently before the court,
Special Master Gowen, citing to Simmons and Amankwaa stated:

       “[R]easonable basis” is an objective consideration of the totality of the
       circumstances except for the statute of limitations or any directly related
       conduct by petitioner’s counsel. Simmons, 875 F.3d at 635; Chuisano, 116
Fed. Cl. at 289. However, this evaluation may include various objective
       factors such as “the factual basis of the claim, the novelty of the vaccine,
       and the novelty of the theory of causation.” Amankwaa v. Sec’y of Health &
       Human Servs., 138 Fed. Cl. 282, 289-90 (2018).

Harding v. Sec’y of Health & Human Servs., 2019 WL 3215974, at *2.

        The respondent, in Ms. Harding’s case, however, argues that Special Master
Gowen misapplied the legal standard for “reasonable basis” set forth by the Federal
Circuit in Simmons v. Secretary of Health & Human Services. Respondent asserts that
the Special Master “found the procedural history, and in particular the decision by
petitioner and her counsel to dismiss the claim, controlling.” Respondent further argues
that:
       [N]owhere in Simmons did the Federal Circuit endorse a “totality of the
       circumstances” test for evaluating reasonable basis. Rather, Simmons
       makes clear that a special master’s reasonable basis analysis must focus
       solely on whether there is objective support in the record for the claim set
       forth in the petition. 875 F.3d at 635-36. The special master’s formulation of
       the holding in Simmons is therefore legally incorrect.
Respondent also argues that because “the conduct of petitioner and her counsel (in
bringing and subsequently dismissing her petition) was plainly critical to the special
master’s reasonable basis analysis,” the decision “contains clear error, and must be
reversed.” Petitioner’s responds:

                                             18
       [T]he Special Master did not consider attorney conduct in ruling that there
       was a reasonable basis to bring petitioner’s claim. Indeed, respondent
       glances over 6-pages of the Special Master’s analysis of the medical record
       to fabricate a story that somehow the focus of his analysis was on attorney
       conduct and not the claim itself.
(footnote omitted). Petitioner’s counsel maintains, however, that because the Special
Master had “(1) ‘considered the relevant evidence of record,’ (2) ‘drawn plausible
inferences,’ and (3) stated, ‘a rational basis for the decision,’ therefore there is no
reversible error. Hines [v. Sec’y of Health & Human Servs.], 940 F.2d 1518, 1528.”
      Respondent further argues that this court also could find legal error in the Special
Master’s decision because:
       [T]he special master did not ground his analysis in an evaluation of the
       objective record evidence. To the contrary, his analysis rested almost
       entirely on his subjective interpretation of the medical records and his
       speculation about what the evidence might have been if petitioner had
       decided to proceed with the case.
It is unfortunate that the Special Master included speculation as to possible “what ifs” a
number of times in his decision, most notably when he mused, “[i]t is entirely possible that
if Dr. Schindler was consulted, he would have expressed concern about the HPV vaccines
being administered during this time period, as he did about the nasal surgery.” Harding v.
Sec’y of Health & Human Servs., 2019 WL 3215974, at *6.11 Nonetheless, the Special
Master’s review of the medical history in the record provides a basis for his award of
attorney’s fees and costs to the petitioner. The Special Master drew specifically from the
petition and the medical records, the objective factors under the Federal Circuit’s
guidance in Simmons v. Secretary of Health & Human Services, to conclude that a flare
of petitioner’s GPA after administration of the HPV vaccination provided the reasonable
basis sufficient to grant petitioner’s request for attorney’s fees and costs.

11In his decision on attorney’s fees and costs, the Special Master also speculated as to
why the petitioner may have had two separate series of the HPV vaccination. Special
Master Gowen stated:

       The medical records from this visit do not reflect the petitioner previously
       completed a three-dose HPV vaccine series back in 2011. It is possible that
       petitioner needed a repeat course of HPV vaccine because her treatment
       for GPA, including chemotherapy drugs, wiped out her immune system. An
       alternative explanation could be that the medical provider giving the HPV
       vaccines in 2014 may not have been aware of the previous HPV vaccines
       administered at a different medical practice back in 2011. At any rate, it
       appears that in 2014, the gynecologist was aware of petitioner’s history of
       GPA but did not see any contraindication for administering the HPV vaccine.
Harding v. Sec’y of Health & Human Servs., 2019 WL 3215974, at *5.
                                            19
        Finally, respondent states that the Special Master made a legal error when he
concluded that “‘a flare of an autoimmune disease shortly after administration of a
covered vaccine,’” was sufficient to establish reasonable basis in this case. Respondent
states:

       While that evidence might have established a reasonable basis if petitioner
       were alleging a Table injury – in which case causation could be presumed
       based solely on proof of onset of the injury within the Table time period – it
       does not support a reasonable basis finding in a causation-in-fact case like
       this one. Indeed, the Federal Circuit has repeatedly held that timing alone
       is insufficient to meet petitioner’s burden of proof in causation-in-fact cases.
       See, e.g., Moberly v. HHS, 592 F.3d 1315, 1323 (Fed. Cir. 2010); W.C. v.
       HHS, 704 F.3d 1352, 1356 (Fed. Cir. 2013); see also Chuisano, 116 Fed.
       Cl. at 287 (“[t]emporal proximity is necessary, but not sufficient” to establish
       reasonable basis).

(alteration in original). Respondent asserts that “neither petitioner nor the special master
has identified any objective evidence in the record addressing the critical issue of
causation,” and argues that “petitioner’s medical records do not document a significant
aggravation of petitioner’s GPA in the time periods after her HPV vaccinations, but rather
only a waxing and waning of symptoms likely associated with fluctuations in medications.”
Respondent contends that it was arbitrary and capricious for the special master to base
his reasonable basis analysis of petitioner’s aggravation claim on “his own subjective
speculation, which was not supported by the medical records or any substantiating
evidence from an expert or treating physician.” Respondent concludes that, “[i]ndeed, the
special master’s findings appear to serve only as a pretext for his primary reason for
finding reasonable basis – i.e., his desire to reward petitioner and her counsel for the
decision to dismiss the claim ‘at an early stage.’”
       Petitioner’s counsel responds, however, that:
       The Special Master’s review of the medical facts of this case in addition to
       the fact that claims that GPA was significantly aggravated by vaccination
       were successfully litigated in this program in the past, provided more than
       enough objective factors necessary to award attorney fees and costs in this
       case.
(footnotes omitted).
       This court agrees that petitioner’s claim does not fall within the Vaccine Injury
Table, and, therefore, is considered a non-Table claim for purposes of recovery under 42
U.S.C. §§ 300aa–11(c)(1), –13(a)(1). See Vaccine Injury Table, 42 C.F.R. § 100.3(a)
(2019). In order to recover under the Vaccine Act, a petitioner “must show, by a
preponderance of the evidence, “that the injury or death at issue was caused by a
vaccine.” Milik v. Sec’y of Health & Human Servs., 822 F.3d 1367, 1379 (Fed. Cir. 2016);
(quoting Broekelschen v. Sec’y of Health & Human Servs., 618 F.3d 1339, 1341 (Fed.
Cir. 2010) (citing 42 U.S.C. §§ 300aa–11(c)(1), –13(a)(1)); see also W.C. v. Sec’y of
Health & Human Servs., 704 F.3d 1352, 1355-56 (Fed. Cir. 2013) (“The Vaccine Act

                                             20
created the National Vaccine Injury Compensation Program, which allows certain
petitioners to be compensated upon showing, among other things, that a person
‘sustained, or had significantly aggravated’ a vaccine-related ‘illness, disability, injury, or
condition.’” (quoting 42 U.S.C. § 300aa–11(c)(1)(C))); Lombardi v. Sec’y of Health &
Human Servs., 656 F.3d 1343, 1350 (Fed. Cir. 2011) (“A petitioner seeking compensation
under the Vaccine Act must prove by a preponderance of the evidence that the injury or
death at issue was caused by a vaccine.”); see also Shapiro v. Sec’y of Health & Human
Servs., 105 Fed. Cl. 353, 358 (2012), aff’d, 503 F. App’x 952 (Fed. Cir. 2013); Jarvis v.
Sec’y of Health & Human Servs., 99 Fed. Cl. 47, 54 (2011).

       As United States Court of Appeals for the Federal Circuit explained:

       A petitioner can establish causation in one of two ways. Id. [Broekelschen
       v. Sec’y of Health & Human Servs., 618 F.3d at 1341] If the petitioner
       shows that he or she received a vaccination listed on the Vaccine Injury
       Table, 42 U.S.C. § 300aa–14, and suffered an injury listed on that table
       within a statutorily prescribed time period, then the Act presumes the
       vaccination caused the injury. Andreu v. Sec'y of Health & Human Servs.,
       569 F.3d 1367, 1374 (Fed. Cir. 2009). Where, as here, the injury is not on
       the Vaccine Injury Table, the petitioner may seek compensation by proving
       causation-in-fact.

Milik v. Sec’y of Health & Human Servs., 822 F.3d at 1379 (citing Andreu v. Sec'y of
Health & Human Servs., 569 F.3d at 1374); see also Grant v. Sec’y of Health & Human
Servs., 956 F.2d 1144, 1147-48 (Fed. Cir. 1992). The Federal Circuit has held that
causation-in-fact in the Vaccine Act context is the same as the “legal cause” in the general
torts context. See Shyface v. Sec’y of Health & Human Servs., 165 F.3d 1344, 1352 (Fed.
Cir. 1999). Therefore, drawing from the Restatement (Second) of Torts, the vaccine is a
cause-in-fact when it is “a substantial factor in bringing about the harm.” de Bazan v.
Sec’y of Health & Human Servs., 539 F.3d 1347, 1351 (Fed. Cir.), reh’g and reh’g en
banc denied (Fed. Cir. 2008) (quoting the Restatement (Second) of Torts § 431(a)); see
also Deribeaux ex rel. Deribeaux v. Sec’y of Health & Human Servs., 717 F.3d 1363,
1367 (Fed. Cir.) reh’g and reh’g en banc denied (Fed. Cir. 2013) (“To prove causation, a
petitioner must show that the vaccine was ‘not only a but-for cause of the injury but also
a substantial factor in bringing about the injury.’” (quoting Shyface v. Sec’y of Health &
Human Servs., 165 F.3d at 1352–53)). A “‘substantial factor’ standard requires a greater
showing than ‘but for’ causation.” de Bazan v. Sec’y of Health & Human Servs., 539 F.3d
at 1351 (quoting Shyface v. Sec’y of Health & Human Servs., 165 F.3d at 1352).
“However, the petitioner need not show that the vaccine was the sole or predominant
cause of her injury, just that it was a substantial factor.” Id. (citing Walther v. Sec'y of
Health & Human Servs., 485 F.3d 1146, 1150 (Fed. Cir. 2007)).

        Under the off-Table theory of recovery, a petitioner is entitled to compensation if
he or she can demonstrate, by a preponderance of the evidence, see 42 U.S.C. § 300aa-
13(a)(1)(A), that the recipient of the vaccine sustained, or had significantly aggravated,
an illness, disability, injury, or condition not set forth in the Vaccine Injury Table, but which

                                               21
was caused by a vaccine that is listed on the Vaccine Injury Table. See 42 U.S.C.
§ 300aa-11(c)(1)(C)(ii)(I); see also LaLonde v. Sec’y of Health & Human Servs., 746 F.3d
1334, 1339 (Fed. Cir. 2014); W.C. v. Sec’y of Health & Human Servs., 704 F.3d at 1356
(“Nonetheless, the petitioner must do more than demonstrate a ‘plausible’ or ‘possible’
causal link between the vaccination and the injury; he must prove his case by a
preponderance of the evidence.” (quoting Moberly ex rel. Moberly v. Sec’y of Health &
Human Servs., 592 F.3d at 1322)); Althen v. Sec’y of Health & Human Servs., 418 F.3d
at 1278; Hines on Behalf of Sevier v. Sec’y of Dep’t of Health & Human Servs., 940 F.2d
at 1525. While scientific certainty is not required, the Special Master “is entitled to require
some indicia of reliability to support the assertion of the expert witness.” Moberly ex rel.
Moberly ex rel. v. Sec’y of Health & Human Servs., 592 F.3d at 1324; see also Hazlehurst
v. Sec’y of Health & Human Servs., 88 Fed. Cl. 473, 439 (2009), aff’d, 604 F.3d 1343
(Fed. Cir. 2010) (quoting Andreu ex rel. Andreu v. Sec’y of Health & Human Servs., 569
F.3d 1367, 1379 (Fed. Cir. 2009)). Therefore, to receive compensation for an aggravation
claim petitioner would have to prove that the HPV vaccination caused aggravation of her
GPA. The burden, however, for establishing reasonable basis in order to recover
attorney’s fees is “something less than the preponderant evidence ultimately required to
prevail on one’s vaccine-injury claim.” Chuisano v. United States, 116 Fed. Cl. at 287
(2014).

        In Hines on Behalf of Sevier v. Secretary of Health & Human Services, the United
States Court of Appeals for the Federal Circuit addressed the correct standard of review
when the issue before the special master was if the evidence submitted by petitioner was
sufficient to conclude that the vaccine had caused the injury. See Hines on Behalf of
Sevier v. Sec’y of Health & Human Servs., 940 F.2d 1518, 1527 (Fed. Cir. 1991). The
Federal Circuit held that if a special master has 1) considered the relevant evidence in
the record, 2) drawn plausible inferences, and 3) articulated a rational basis for the
decision, then “reversible error will be extremely difficult to demonstrate” under the
arbitrary and capricious standard of review. See id. at 1528.

        In Ms. Harding’s case, Special Master Gowen’s decision suggests that he
reviewed over 2,000 pages of medical records submitted by petitioner in order to conduct
his rational basis analysis. The Special Master determined that “the medical records
documenting a flare of an autoimmune disease shortly after administration of a covered
vaccine provided reasonable basis for filing this petition.” In a footnote to his decision, the
Special Master noted that in drafting the section of the decision for the period between
the onset of petitioner’s GPA and her second series of HPV vaccines, he relied on
respondent’s response to the motion for attorney’s fees and costs, “but the Court has
independently reviewed the medical records and added additional details.” Harding v.
Sec’y of Health & Human Servs., 2019 WL 3215974, at *4 n.7. The Special Master’s
decision includes numerous citations to petitioner’s medical records, in the exhibits
petitioner filed with the court, demonstrating his review and familiarity with the medical
records before issuing his decision. For example, the Special Master’s decision states in
part:

                                              22
      On July 7, 2014, Dr. Schindler recorded that petitioner had worsened
      breathing and hearing. He increased prednisone to 40 mg/ day for 2 weeks,
      then decreased to 30 mg/ day for one month. Pet. Ex. 1 at 16-20. On July
      15, 2014, Dr. Schindler performed another surgical dilation of her airway.
      Pet. Ex. 1 at 98-103. It was noted at this time that her lungs were affected.
      Pet. Ex. 10 at 298. She was doing better after this on Cytoxan and weaning
      prednisone doses. Id. at 361, 447, 516.

Harding v. Sec’y of Health & Human Servs., 2019 WL 3215974, at *5. Special Master
Gowen also quoted directly from the petitioner’s exhibits in his decision, sometimes in
some detail. For example:

      Two days after receiving the first HPV vaccine at issue in this claim, on
      October 30, 2014, petitioner presented to her surgeon Dr. Schindler for a
      follow-up. She was taking prednisone at 17.5 mg daily as well as
      methotrexate. She reported feeling “good” and had no complaints of
      shortness of breath on exertion, noisy breathing, or upper respiratory
      infection. She planned to undergo a rhinoplasty to correct the saddle nose
      deformity in December 2014 (in approximately two months’ time). After
      performing a physical evaluation, Dr. Schindler assessed that petitioner’s
      “previously diagnosed granulomatosis with polyangiitis (GPA) does not
      appear at this time.” Pet. Ex. 1 at 44-45. His assessment continued:

             I have grave concerns about her undergoing rhinoplasty in the
             next couple of months, however. She has not demonstrated
             adequacy of her immunosuppression off prednisone yet and I
             fear that surgery to correct her saddle nose deformity and
             septal perforation could “reawaken” her disease. I would like
             to see her stably managed on methotrexate and quiescent for
             several months before surgery on a known site of activity for
             her. I fear that withdrawal of her immunosuppression around
             surgery for more than a brief period could result in reactivation
             of the GPA and loss of the reconstruction. We talked about
             this for a while and I promised that I would review my thoughts
             with Dr. Wang and Dr. Garg. My thoughts for her nasal
             surgery would be more like 6 months from now with
             demonstrated quiescence on methotrexate and off oral
             steroids. She was extremely disappointed by this, but I really
             think that there is one good opportunity to the nasal
             reconstruction and I have seen this operation fail in patients
             with continued disease activity. She will need very careful
             management of her immunosuppression through surgery to
             help prevent flare. I do believe that she can continue her
             inhaled corticosteroid for the subglottic and bronchial disease
             and topical nasal steroid may be useful around the time of
             nasal surgery.

                                            23
        Id. at 45. Dr. Schindler increased prednisone to 27.5 mg/ day for 2 weeks,
        then down to 25 mg/ day for 2 weeks. He planned to see petitioner again in
        three months or sooner if symptoms worsened. Id. at 45-46.

Id.

     After summarizing his findings from petitioner’s medical records, Special Master
Gowen stated:

        The medical records from late September and October 2014 do not
        expressly say that petitioner was in “remission” before receiving the HPV
        vaccines at issue in the significant aggravation claim. However, those
        records do suggest that her condition was improving and approaching
        quiescience [sic]. Additionally, the medical records reflect that within 30
        days after petitioner received the first HPV vaccine at issue, petitioner did
        experience of [sic] GPA. Indeed, within 45 days after the HPV vaccine, Dr.
        Schindler, the doctor managing her GPA, confirmed the flare and recorded
        that her condition was “inadequately controlled.”

        I find particularly persuasive Dr. Schindler’s concern about activation of
        petitioner’s GPA, an autoimmune condition, during the tapering down of
        prednisone. Dr. Schindler specifically advised against nasal surgery which
        petitioner wanted to undergo. He does not mention the advisability of HPV
        or any other vaccines during the tapering down of prednisone. He may not
        have been asked about the HPV vaccines or aware that petitioner received
        them (from a different medical provider). It is entirely possible that if Dr.
        Schindler was consulted, he would have expressed concern about the HPV
        vaccines being administered during this time period, as he did about the
        nasal surgery.

Id. at *6.

       Respondent characterizes the Special Master’s statements as the Special
Master’s “subjective interpretation of the medical records.” Notwithstanding the pure
speculation in the last sentence quoted immediately above, the medical records provided
by petitioner from her visit with Dr. Schindler on September 28, 2014 state that Dr.
Schindler saw “no signs of active nasal or subglottic granulomatosis with polyangiitis
(GPA),” between the first and second series of the HPV vaccination petitioner received.
As indicated in petitioner’s exhibits submitted to Special Master Gowen, petitioner
received the first shot in the second series of HPV vaccinations on October 28, 2014, and
the physician who administered the shot to petitioner noted no signs of respiratory
distress or abnormalities in petitioner upon physical examination that day. See id. at *5.
Petitioner received the second shot in the series of HPV vaccinations at issue on
November 25, 2014 and the next day presented to her primary care practice complaining
of stomach discomfort, urine smelling of ammonia, decreased appetite, loose stools,
fatigue, and dry skin for two weeks. See id. at *6. On December 2, 2014, petitioner’s
                                             24
primary care physician Dr. Rampton assessed petitioner as having “Wegener’s
granulomatosis” with a note about tapering steroids, as well as headache, depression,
and anxiety, although he attributed it to “[s]teroid withdrawal.” On December 15, 2014,
Dr. Schindler assessed petitioner as having inadequately controlled GPA.

         This court finds that the Special Master’s evaluation of reasonable basis is
consistent with the Federal Circuit’s holding in Simmons. Although the Special Master
referred to the totality of the circumstances when describing the reasonable basis
standard in his decision on attorney’s fees and costs, indicating, “[i]n contrast to good
faith, ‘reasonable basis’ is an objective consideration of the totality of the circumstances
except for the statute of limitations or any directly related conduct by petitioner's counsel.”
Simmons, 875 F.3d at 635; Chuisano, 116 Fed. Cl. at 289,” Harding v. Sec’y of Health &
Human Servs., 2019 WL 3215974, at *2, Special Master Gowen’s decision focused on
objective considerations in the record, such as petitioner’s more that 2,000 pages of
medical records.

        Moreover, the Special Master specifically acknowledged the holding of the United
States Court of Federal Claims in Amankwaa, that the evaluation of reasonable basis
should be based on various objective factors. Although Special Master Gowen discussed
petitioner’s and her counsel’s decision to request a dismissal of her claim, as well as
extrapolated from his prior experience as a special master in the Vaccine Program as to
the reasons why petitioner and petitioner’s counsel may have sought a dismissal, his
speculative comments were not the primary basis to award attorney’s fees and costs. In
his decision, the Special Master plainly states: “I find that the medical records
documenting a flare of an autoimmune disease shortly after administration of a covered
vaccine provided reasonable basis for filing this petition and for pursuing it until the
voluntary dismissal at an early stage.” Harding v. Sec’y of Health & Human Servs., 2019
WL 3215974, at *7 (footnote omitted). The Special Master’s decision focused far more on
the review of over 2,000 pages of medical records, including descriptions of petitioner’s
GPA symptoms and HPV vaccinations, than on court procedures or the actions of
petitioner’s attorney when or after the petition was filed and when the fees were sought.

        This court finds that the objective evidence in the record provided an adequate
basis upon which Special Master Gowen could arrive at the determination that petitioner’s
medical records “suggest that her condition was improving and approaching quiescience.
Additionally, the medical records reflect that within 30 days after petitioner received the
first HPV vaccine at issue, petitioner did experience of GPA. Indeed, within 45 days after
the HPV vaccine, Dr. Schindler, the doctor managing her GPA, confirmed the flare and
recorded that her condition was ‘inadequately controlled.’” It is correct that the Special
Master did not cite to evidence in the medical records that specifically mention the HPV
vaccination as the cause or significant contributing factor to the aggravation of petitioner’s
GPA. The Special Master, however, could, and did, find a “reasonable basis” to award
attorney’s fees and costs, in the medical records submitted to the court at the time the
petition was filed and in subsequently submitted medical records prior to petitioner asking
to dismiss the claims in order to try to demonstrate that the HPV vaccination was the
cause or significant contributing factor of the aggravation of petitioner’s GPA.

                                              25
       In his decision, the Special Master also recognized that there have been previous
awards for compensation in cases raising GPA based claims, although none of the
decisions cited included an HPV vaccination, at issue in this case. See id. at *3 (citing
Rosa v. Sec’y of Health & Human Servs., No. 14-886V, 2017 WL 1401365 (Fed. Cl. Spec.
Mstr. Mar. 24, 2017); Purgason v. Sec’y of Health & Human Servs., No. 12-465V, 2016
WL 1627575 (Fed. Cl. Spec. Mstr. April 4, 2016); Fields v. Sec’y of Health & Human
Servs., No. 02-311V, 2008 WL 222241 (Fed. Cl. Spec. Mstr. May 14, 2008); Schrum v.
Sec’y of Health & Human Servs., No. 04-210V, 2006 WL 1073012 (Fed. Cl. Spec. Mstr.
Mar. 31, 2006)).

        Respondent argues that “without affirmative evidence from an expert or treating
physician that the HPV vaccine actually caused or significantly aggravated petitioner’s
GPA, her claim had no feasibility of success,” and, therefore, the Special Master could
not find a “reasonable basis.” Respondent appears to conflate the evidentiary standard
required for an award of compensation for a non-Table injury with the standard required
to prove “reasonable basis” for an award of attorney’s fees and costs. Moreover, the
statute does not draw a distinction between Table and non-Table injuries when providing
for awards of attorney’s fees and costs before a case goes through complete evidence
presentation. See 42 U.S.C. § 300aa-15(e)(1). While Special Master Gowen notes that
he likely would have asked petitioner to seek an expert opinion if the case had proceeded,
petitioner had not engaged an expert at the time she sought to dismiss her petition, nor
had she obtained all of the medical records she indicated that she was trying to obtain to
file with the court. The absence of an expert opinion in support of her case at the time her
petition was dismissed does not preclude an award of attorney’s fees and costs.

        As indicated above, the Federal Circuit in Hines on Behalf of Sevier v. Secretary
of Health & Human Services, held that if a special master has 1) considered the relevant
evidence in the record, 2) drawn plausible inferences, and 3) articulated a rational basis
for the decision, then “reversible error will be extremely difficult to demonstrate” under the
arbitrary and capricious standard of review. Hines on Behalf of Sevier v. Sec’y of Health
& Human Servs., 940 F.2d at 1528. The Special Master did not act arbitrarily or
capriciously in determining that petitioner had a reasonable basis for filing her claim based
on the record to date before the Special Master at the time petitioner requested dismissal
of her case. Although indicating he was considering “reasonable basis” to be an objective
consideration of the totality of the circumstances, Special Master Gowen was able to rely
on the objective medical records to reach his decision on attorney’s fees and costs.

         Respondent also offered policy arguments as to why it believes no fees or costs
should be awarded in this case. Respondent argues that “special masters already grant
a generous concession to the petitioners’ bar when they permit petitioners’ counsel to file
deficient petitions and supplement them post-filing in an attempt to establish, at a
minimum, a reasonable basis for the claim.” Respondent maintains that according to the
billing records provided by petitioner’s counsel in this case, counsel was first contacted
by petitioner in April 2015 and, therefore, had sufficient time to fully investigate petitioner’s
claim with the United States Court of Federal Claims Office of Special Masters before
filing in October 2017. Respondent states:

                                               26
       The special master’s Decision in this case reflects his apparent view that
       Congress intended for petitioners’ counsel to be reimbursed for their time
       and costs incurred in connection with investigating essentially every case
       filed under the Act, even when evidence to support critical elements of the
       claim ultimately is not produced. Stated otherwise, the special master
       appears to believe that petitioners’ counsel should always be paid for
       investigating their clients’ claims, even when a reasonable basis for the
       claim ultimately is not established, so long as counsel dismisses the claim
       promptly upon determining that the claim has no merit.

       Not only is such an approach inconsistent with the plain language of
       Sections 11(c) and 15(e)(1), it inevitably results in the filing of Vaccine Act
       cases that have no possibility of success on their merits. If the special
       master’s Decision is upheld, it will only encourage petitioners’ attorneys to
       “game the system” by waiting until after a petition is filed to determine
       whether the claim can be supported with objective evidence, so that they
       can be reimbursed for their investigation into the claim. At a time when the
       resources of the Court and respondent are being stretched to their limits
       due to the extraordinary number of Vaccine Act petitions being filed, it does
       not make sense from either a policy or practical standpoint to compensate
       counsel for bringing cases that have no chance of success. In fact, by
       including the reasonable basis requirement in Section 15(e) of the Act,
       Congress almost certainly intended the opposite result.
In response to respondent’s policy arguments, petitioner’s counsel states:
       The law of this Circuit is clear, an expert report is not a requirement to
       establish reasonable basis for attorney fees and costs. There must be some
       way of obtaining an award of attorney fees and costs when no expert report
       is proffered. The respondent argues that there must be some other direct
       evidence of vaccine causation, such as a causal connection made by the
       treating physician, in the medical records in order to find reasonable basis.
       Not only is this proposed requirement not the law of this Circuit, but it goes
       against the very nature of these medically complicated cases . . . .
       In this case, there is no question that GPA is a rare condition that has been
       compensated by the VICP [Vaccine Injury Compensation Program]. The
       Special Master analyzed the record determining that there was evidence
       that Ms. Harding suffered a flare of the condition shortly after receiving a
       covered vaccine. That should be enough to establish reasonable basis. If
       this Court decides that direct evidence of vaccine causation is required for
       attorney fees and costs, then this program will face an attorney crisis in
       addition to the petitioner expert one that we are now experiencing.
(footnote omitted).
      The Court of Appeals for the Federal Circuit summarized the purpose of the
National Vaccine Injury Compensation Program in Cloer v. Secretary of Health & Human
Services, stating:

                                             27
         The overarching purpose of the Vaccine Act and the National Childhood
         Vaccine Injury Compensation Program it created is to award compensation
         “to vaccine-injured persons quickly, easily, and with certainty and
         generosity.” H.R. Rep. No. 99-908, at 3. Remedial legislation like the
         Vaccine Act should be construed in a manner that effectuates its underlying
         spirit and purpose. See Atchison, Topeka, & Santa Fe Ry. Co. v. Buell, 480
U.S. 557, 561-62, 107 S. Ct. 1410, 94 L. Ed. 2d 563 (1987). Our
         interpretation of the statute fulfills congressional intent and the Act’s
         legislative purpose. Congress acknowledged that “[l]awsuits and settlement
         negotiations can take months and even years to complete. Transaction
         costs—including attorneys’ fees and court payments—are high. And in the
         end, no recovery may be available. Yet futures have been destroyed and
         mounting expenses must be met.” H.R. Rep. No. 99-908, at 6. Congress
         recognized that having to shoulder attorneys’ fees could deter victims of
         vaccine-related injuries from seeking redress.
Cloer v. Sec’y of Health & Human Servs., 675 F.3d 1358, 1362 (Fed. Cir. 2012), aff’d,
569 U.S. 369 (2013). As described above, regarding attorney’s fees and costs, the
Vaccine Act at 42 U.S.C. § 300aa-15(e)(1), specifically provides:
         (1) In awarding compensation on a petition filed under section 300aa-11 of
         this title the special master or court shall also award as part of such
         compensation an amount to cover--
               (A) reasonable attorneys’ fees, and
               (B) other costs, incurred in any proceeding on such petition. If
               the judgment of the United States Court of Federal Claims on
               such a petition does not award compensation, the special
               master or court may award an amount of compensation to
               cover petitioner's reasonable attorneys' fees and other costs
               incurred in any proceeding on such petition if the special
               master or court determines that the petition was brought in
               good faith and there was a reasonable basis for the claim for
               which the petition was brought.
42 U.S.C. § 300aa-15(e)(1).
        It has been acknowledged by the Court of Appeals for the Federal Circuit that
Congress did not intend that all claimants be eligible for an award of attorney’s fees
whether or not they are eligible to receive compensation. See Perreira v. Sec’y of Health
& Human Servs., 33 F.3d at 1376 (finding that the funds available under the statute are
limited). As explained by the United States Supreme Court, however, “[a]ttorney’s fees
are provided, not only for successful cases, but even for unsuccessful claims that are not
frivolous. These awards are paid out of a fund created by an excise tax on each vaccine
dose.”12 Bruesewitz v. Wyeth LLC, 562 U.S. 223, 229 (2011) (footnotes omitted). The

12   The Supreme Court explained that:

                                             28
respondent does not allege, nor does this court find, that petitioner’s claims were
frivolous. Moreover, as indicated by a Judge of the United States Court of Federal Claims,
the purpose of the fee-shifting provision is to “ensure that vaccine-injury claimants will
have readily available a competent bar to prosecute their claims under the [Vaccine] Act.”
Scalon v. Sec’y of Health & Human Servs., 116 Fed. Cl. 629, 634 (2014) (quoting
Saunders v. Sec’y of Health & Human Servs., 25 F.3d 1031, 1035 (Fed. Cir. 1994))
(alternation in original).
        Taking into account various objective factors “is consistent with the underlying
spirit and purpose of the Vaccine Act, and strikes the right balance between an award of
fees to counsel who have represented unsuccessful claimants and the statutorily
expressed congressional intent to impose some limitations on fee awards.” Chuisano v.
United States, 116 Fed. Cl. at 290. Special Master Gowen based his decision on the
objective medical records provided by petitioner when deciding to award attorney’s fees
and costs to petitioner, even though her claim was unsuccessful and petitioner asked to
have her petition dismissed before fully litigating it. The purpose of the Vaccine Program
is not to discourage the sincere petitioners from bringing claims, even if they are ultimately
unsuccessful. The Vaccine Program also does not seek to dissuade attorneys from
representative petitioners who have a reasonable basis and chance of success when
filing a claim. A special master can award attorney’s fees and costs even to an
unsuccessful petitioner, provided the claim was brought in good faith and petitioner had
a reasonable basis for filing the claim. See 42 U.S.C. § 300aa-15(e)(1). The Special
Master did so in this case.
                                      CONCLUSION
       Upon review of the record before the court, Special Master Gowen’s June 18, 2019
decision to grant petitioner attorney’s fees and costs of $17,366.96 was not an abuse of
discretion, nor was it arbitrary or capricious. Therefore, respondent’s motion for review is
hereby DENIED.

       IT IS SO ORDERED.

                                                        s/Marian Blank Horn
                                                        MARIAN BLANK HORN
                                                                 Judge

       The quid pro quo for this, designed to stabilize the vaccine market, was the
       provision of significant tort-liability protections for vaccine manufacturers.
       The Act requires claimants to seek relief through the compensation program
       before filing suit for more than $1,000. Manufacturers are generally
       immunized from liability for failure to warn if they have complied with all
       regulatory requirements (including but not limited to warning requirements)
       and have given the warning either to the claimant or the claimant’s
       physician.

Bruesewitz v. Wyeth LLC, 562 U.S. at 229 (emphasis in original; footnotes omitted).
                                             29